Expert opinion from Marcella Abunahman Pereira Specialization in Clinical Cardiology · 12 years of experience · Brazil ...
Treatment is a minimum of six months where combination tablets are taken. It is sad to note that 25% of those who are started ...
Bimekizumab is well tolerated and produces clinically meaningful responses in patients with hidradenitis suppurativa, ...
Patients with hidradenitis suppurativa are more likely to develop cardiovascular disease, according to the largest study ...
BE HEARD I and BE HEARD II are the first Phase 3 trials to evaluate the efficacy and safety of an IL-17A and IL–17F inhibitor, BIMZELX ® (bimekizumab-bkzx), in the treatment ...